Polycystic Kidney Disease – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of polycystic kidney disease comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of polycystic kidney disease for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s polycystic kidney disease forecast will answer the following questions:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of uveitis over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts the following patient populations:

  • Diagnosed prevalent ARPKD
  • Diagnosed incident ARPKD
  • Diagnosed prevalent ADPKD
  • Diagnosed definite prevalent ADPKD
  • Diagnosed likely prevalent ADPKD
  • Diagnosed possible prevalent ADPKD

Note: Coverage may vary by country.

Table of contents

  • Polycystic Kidney Disease - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
        • Key Updates
      • Total Prevalence of Autosomal Dominant Polycystic Kidney Disease per 100,000 Among People of All Ages in 2021 and 2041
      • Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Autosomal Dominant Polycystic Kidney Disease Over the Next Twenty Years
      • Total Prevalence of Autosomal Dominant Polycystic Kidney Disease per 100,000 Among People of All Ages in 2021 and 2041
      • Analysis of the Total Prevalent Cases of Autosomal Dominant Polycystic Kidney Disease in 2021 by Disease Confirmation Status
    • Epidemiology Data
    • Methods
      • Diagnosed prevalent ADPKDtt
      • Diagnosed prevalent ADPKD by Disease Confirmation Statusttttt
      • Diagnosed Prevalent and Incident ARPKD
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of PKD
        • Studies Excluded From the Analysis of PKD
      • Risk / Protective Factors
        • Risk / Protective Factors for Uveitis
      • Bibliography
      • Abbreviation Table
      • Glossary